CTN-0110: Randomized, Double-Blind, Placebo-Controlled Trial of Monthly Injectable Buprenorphine For Methamphetamine Use Disorder (MURB)

Steve Shoptaw, PhD
Lead Investigator

University of California, Los Angeles

The fourth wave of the opioid crisis involves increasing polydrug stimulant and opiate use. Incidence of overdose deaths due to polysubstance use involving opioids co-occurring with methamphetamine increased from 2017 to 2018 by 14.6%. According to the National Survey on Drug Use and Health in 2018, an estimated 1,867,000 of persons in US aged 12 years and older, reported methamphetamine use in the past year and 1,051 000 reported substance use disorder in the past year involving methamphetamines. There are no effective medications for treating methamphetamine use disorder. This proposal will test the superiority of long-acting buprenorphine (and its kappa antagonist activity) over placebo as a treatment for methamphetamine use disorder among persons who co-use opioids.

    Node Involvement

    Lead Node(s):

  • Big South/West Node

  • All Participating Nodes:

  • Big South/West Node
  • Pacific Northwest Node